HGH Fragment 176-191 Peptide Research – Complete Guide

Table of Contents

• Quick Facts
• What is HGH Fragment 176-191?
• Molecular Structure and Core Properties
• Mechanisms of Action Being Investigated
• Major Areas of Research
• Pharmacokinetics and Biological Distribution
• Research Limitations and Evidence Gaps
• Regulatory and Research Status
• Key Research Findings
• Frequently Asked Questions
• References

Quick Facts

• Primary Research Areas: Fat metabolism, lipolysis, thermogenesis, cartilage repair, oncology (emerging)
• Structural Origin: Amino acids 176-191 of full human growth hormone sequence
• Molecular Weight: Approximately 1,815.1 g/mol
• Research Status: Research chemical; no FDA-approved therapeutic indication
• Key Mechanisms: Hormone-sensitive lipase activation, beta-3 adrenergic receptor interaction, antilipogenic activity, cAMP/PKA pathway involvement
• Published Studies: Foundational preclinical data from 1978 onward; human analogue data from AOD9604 trials covering approximately 900 subjects across six trials
• Clinical Trial Status: No active FDA-approved clinical trials identified as of early 2026; closest human data comes from AOD9604 (modified form) trials
• Regulatory Classification: Research chemical only; not approved for human consumption; not eligible for compounding under FDA Category 1; prohibited by WADA in competitive athletics

What is HGH Fragment 176-191?

HGH Fragment 176-191 is a synthetic peptide corresponding to amino acids 176 through 191 at the C-terminal end of full human growth hormone (hGH). Researchers isolated this region of the growth hormone sequence after observing that the fat-metabolizing properties of hGH appeared to reside in a specific structural domain rather than being distributed across the entire 191-amino acid protein. By isolating and synthesizing just this 16-amino acid fragment, scientists created a research tool for studying selective fat metabolism without triggering the full biological profile of the parent hormone.

The discovery that a small peptide fragment could replicate specific metabolic activities of a much larger protein generated significant research interest. Full human growth hormone drives growth, tissue repair, protein synthesis, and fat metabolism through multiple receptor pathways and downstream signaling cascades. Many of hGH’s non-metabolic effects, including IGF-1-mediated growth promotion and insulin resistance, are considered undesirable for research focused strictly on fat oxidation. HGH Fragment 176-191 appears to lack high affinity for the canonical growth hormone receptor, which researchers believe explains its selective metabolic profile.

A closely related compound, AOD9604, represents a stabilized and modified version of this fragment. Much of the available human clinical data comes from AOD9604 trials rather than the unmodified fragment itself. While the two share core structural features, their pharmacological profiles are not identical, and findings from AOD9604 research cannot be directly applied to Fragment 176-191 without independent confirmation.

Foundational research on this peptide dates to 1978, when early in vivo rat studies confirmed its metabolic activity. Research interest continued through the 1990s and 2000s, with the most recent published work from 2022 exploring cancer biology applications. The compound remains strictly classified as a research chemical with no approved therapeutic use in any major jurisdiction.

Molecular Structure and Core Properties

Chemical Structure and Specifications

Key Structural Features

The 176-191 sequence contains two cysteine residues that form a disulfide bond, creating a structural loop that is central to the peptide’s biological activity. This disulfide bridge contributes to conformational stability and is believed to be important for receptor interactions within adipose tissue. Research on shorter variants of this fragment, including the 179-191 sequence, demonstrated that removing the 176-179 segment eliminates certain metabolic effects, establishing that the full 176-191 sequence is functionally necessary for the complete activity profile [1].

The C-terminal region of growth hormone from which this fragment derives is structurally distinct from the receptor-binding domains responsible for growth promotion. This separation of functional domains within the hGH sequence is what allows the fragment to maintain metabolic activity while showing low affinity for the canonical growth hormone receptor. Researchers use this structural independence as a tool for dissecting the different biological activities of the parent hormone [2].

The lyophilized powder form used in research settings requires reconstitution with appropriate solvents prior to use. Stability data from commercial research-grade preparations indicates purity typically exceeding 98%, though quality varies across suppliers, which is an important consideration for experimental reproducibility.

Mechanisms of Action Being Investigated

HGH Fragment 176-191 engages multiple metabolic pathways, all of which center on fat metabolism while bypassing the growth-promoting signaling of the full growth hormone. The central mechanistic distinction from hGH is low affinity for the canonical growth hormone receptor, which redirects its biological activity toward separate adipose-targeted pathways [2].

Hormone-Sensitive Lipase Activation and Lipolysis

The primary mechanism under investigation is activation of hormone-sensitive lipase (HSL) within adipocytes. HSL catalyzes the hydrolysis of stored triglycerides into free fatty acids and glycerol, a process that reduces fat cell size and releases fatty acids for oxidation. This lipolytic activity is concentrated in visceral fat depots in animal models, making it particularly relevant to research on metabolically active fat tissue [4].

This mechanism mirrors the fat-mobilizing action of full hGH but occurs without engaging the growth-promoting receptor pathways. The selectivity for HSL activation without broad receptor engagement is what defines the compound’s research profile as a targeted metabolic tool rather than a growth-promoting agent.

Antilipogenic Activity

Beyond breaking down existing fat stores, the peptide inhibits lipogenesis, the synthesis of new fat from precursor molecules. Studies on both Fragment 176-191 and AOD9604 demonstrate antilipogenic activity in preclinical rodent models and ex vivo human adipose tissue preparations [4]. Interestingly, some assays recorded antilipogenic effects matching the potency of intact hGH without producing equivalent increases in glycerol release, suggesting that lipolytic and antilipogenic activities may operate through partially independent pathways.

AOD9604, the modified form, demonstrates more robust combined antilipogenic and lipolytic activity in obese rodent models and ex vivo human adipose tissue than the unmodified fragment in some study comparisons [4].

Beta-3 Adrenergic Receptor Interaction

The peptide interacts with beta-3 adrenergic receptors in adipose tissue and muscle. Beta-3 adrenergic signaling promotes thermogenesis and lipolysis, particularly in brown adipose tissue. Heffernan et al. demonstrated that AOD9604’s effects in obese mice were diminished in beta-3 adrenergic receptor knockout animals, directly implicating this receptor pathway in the fragment’s metabolic activity [2]. This receptor interaction provides a mechanistic pathway that is functionally separate from growth hormone receptor signaling.

Critically, this beta-3 adrenergic pathway produces metabolic effects without generating the insulin resistance that results from full hGH’s receptor engagement. Studies have not detected impaired glucose tolerance or increased insulin resistance from Fragment 176-191 at the doses used in animal research [6].

Glycogen Metabolism and Glucose Homeostasis Effects

Early in vivo rat studies from 1978 established that Fragment 176-191 modulates glycogen metabolism by favoring glycogenolysis, the breakdown of stored glycogen. This activity alters the Cori cycle, a metabolic loop that recycles lactate from peripheral tissues back to glucose in the liver [1].

At doses of 5 nmol/kg in rats, the fragment produced transient hyperglycemia and sustained increases in plasma insulin. The 179-191 shorter fragment did not produce these same effects, confirming that the 176-179 segment is functionally critical for glucose and insulin modulation. Researchers treat this finding as a relevant mechanistic distinction when designing experimental protocols involving blood glucose measurement [1].

cAMP/PKA Signaling Pathway

The fragment is proposed to indirectly engage the cyclic AMP and protein kinase A (cAMP/PKA) signaling cascade through adenylyl cyclase activation. This pathway drives protein phosphorylation events relevant to fat metabolism within adipocytes, and beta-3 adrenergic receptor activation is a well-established upstream trigger for adenylyl cyclase and subsequent cAMP accumulation in fat cells [11]. Current evidence linking this specific pathway to Fragment 176-191 is extrapolated from broader adrenergic signaling research rather than directly demonstrated, and it represents an area where dedicated mechanistic studies are still needed.

IGF-1 Independence and Growth Hormone Receptor Low Affinity

Fragment 176-191 does not significantly stimulate IGF-1 production. Clinical trial data from AOD9604 trials confirmed no increases in IGF-1 levels in human subjects [6]. Since IGF-1 mediates the anabolic and tissue-building activities of full hGH, the absence of IGF-1 stimulation means the fragment lacks growth-promoting, muscle-building, and hypertrophic effects. The fragment also shows weak mitogenic activity and can antagonize intact hGH at high doses, a property that reinforces its mechanistic distinction from the parent hormone [2].

Major Areas of Research

Research on HGH Fragment 176-191 spans several biological areas, with fat metabolism as the dominant focus and emerging investigations in orthopedics and oncology representing newer directions.

Fat Metabolism and Obesity Research

Fat metabolism research forms the core of HGH Fragment 176-191 investigation. Studies in obese rodent models, primarily ob/ob mice with genetic obesity, used oral administration of AOD9604 and demonstrated reduced weight gain, boosted fat oxidation, and altered adipose tissue metabolism without affecting food intake [4]. These findings attracted significant research attention because the effects occurred without the feeding suppression that confounds many obesity research models.

In murine models, the peptide promotes thermogenesis and lipolysis through beta-3 adrenergic receptor interactions in both adipose tissue and muscle. Energy expenditure measurements in obese rodents treated with AOD9604 showed increased fat oxidation compared to controls [4].

Ex vivo studies using human adipose tissue from obese donors confirmed that AOD9604 enhances lipolysis, promotes fat oxidation, and reduces lipogenesis in human tissue samples. These ex vivo findings are methodologically significant because they suggest at least partial translatability of rodent data to human adipose biology, though in vivo human confirmation remains absent [4].

Key Research Highlights:

• Reduced weight gain and increased fat oxidation in ob/ob obese mice without food intake suppression
• Antilipogenic activity confirmed in both rodent models and ex vivo human adipose tissue
• Thermogenic effects via beta-3 adrenergic receptor interaction in adipose tissue and muscle
• No insulin resistance detected in metabolic studies at research doses

Breast Cancer Biology Research

A 2022 series of studies represents the most recent primary research on Fragment 176-191 and introduced an entirely new application area. Computational molecular docking studies evaluated the peptide’s binding affinity to breast cancer cell receptors including Ki-67, MiB protein, and the estrogen receptor, with high-affinity binding confirmed across these targets [7].

The most quantitatively significant finding concerned doxorubicin enhancement. When Fragment 176-191 was present, the doxorubicin inhibition constant for the progesterone receptor decreased from 139.01 nM to 14.41 nM, representing approximately a tenfold improvement in binding affinity. The binding energy for this interaction improved from -10.09 to -11.31 kcal/mol [7].

This research extended to drug delivery applications. Investigators loaded Fragment 176-191 alongside doxorubicin into chitosan nanoparticles and tested the combination against MCF-7 breast cancer cells, a standard human breast cancer cell line. The peptide-nanoparticle combination demonstrated improved nanoparticle physical properties (size, polydispersity index, and zeta potential), enhanced cytotoxicity against MCF-7 cells compared to doxorubicin alone, and improved anti-proliferative activity in cell viability assays [7].

Key Research Highlights:

• High-affinity computational binding to Ki-67, MiB protein, and estrogen receptor in breast cancer models
• Approximately tenfold improvement in doxorubicin binding affinity for progesterone receptor when peptide is present
• Enhanced MCF-7 breast cancer cell cytotoxicity in chitosan nanoparticle drug delivery system
• These findings are preliminary computational and cell culture data requiring extensive further validation

Cartilage and Bone Repair Research

A 2015 rabbit model study tested the combination of Fragment 176-191 with hyaluronic acid injections and found greater cartilage growth compared to hyaluronic acid treatment alone [8]. This finding positioned the peptide as a potential adjuvant for cartilage repair research, with ongoing investigation targeting osteoarthritis and bone repair applications.

The mechanistic basis for cartilage effects is less well characterized than the metabolic pathways. Researchers have proposed that the peptide’s interaction with local tissue signaling may support chondrocyte activity, but dedicated mechanistic work in this area remains limited. Orthopedic applications represent an early-stage research direction compared to the more established fat metabolism literature.

Key Research Highlights:

• Greater cartilage growth with Fragment 176-191 plus hyaluronic acid versus hyaluronic acid alone in rabbit models
• Potential applications in osteoarthritis research under investigation
• Mechanistic basis for cartilage effects not yet fully characterized

Peptide Blend Research

Laboratory investigations have examined Fragment 176-191 in combination with Mod GRF 1-29, a growth hormone-releasing hormone analogue, and Ipamorelin, a ghrelin mimetic and growth hormone secretagogue. These blend studies in laboratory settings suggested potential complementary effects including growth hormone release enhancement, fat oxidation activity, and tissue repair signals. The theoretical rationale centers on combining Fragment 176-191’s direct fat-metabolizing properties with compounds that stimulate endogenous growth hormone release, potentially creating a complementary metabolic environment [2,4].

These blend findings have not been validated in human trials. This remains a preliminary area without controlled trial data to support specific conclusions.

Key Research Highlights:

• Proposed complementary fat-oxidation and growth hormone effects in combination with Mod GRF 1-29 and Ipamorelin in laboratory settings
• No human trial validation of blend-specific effects
• Mechanistic rationale based on complementary pathway engagement rather than direct evidence

AOD9604 Human Clinical Trial Data

While AOD9604 is a modified form of Fragment 176-191 rather than the identical compound, its six completed clinical trials covering approximately 900 subjects provide the closest available human analogue data. Intravenous doses ranging from 25 mcg/kg to 400 mcg/kg and oral doses from 9 mg to 54 mg were studied across these trials [6].

Safety findings across five of the six trials were consistently favorable: no significant changes in physical examinations, vital signs, laboratory parameters, ECG readings, blood glucose levels, or IGF-1 levels. Adverse event rates were comparable to placebo and no serious adverse events were reported [6].

Efficacy results were less consistent. Weight outcomes were described as mixed and modest across trials, and the lipolytic effects observed did not meet the efficacy thresholds required for FDA drug approval. These results informed the decision not to pursue regulatory approval for AOD9604 as an anti-obesity therapeutic.

Key Research Highlights:

• Favorable short-term safety profile across approximately 900 subjects in AOD9604 trials
• No insulin resistance, glucose intolerance, or IGF-1 elevation detected in human subjects
• Weight loss outcomes described as modest and inconsistent across trial designs
• Efficacy insufficient for FDA drug approval pathway

Pharmacokinetics and Biological Distribution

Absorption and Bioavailability

Most preclinical research on HGH Fragment 176-191 uses subcutaneous injection, which provides direct systemic delivery. Oral administration was tested in AOD9604 rodent studies and showed bioactivity in animal models, though oral bioavailability data for the unmodified fragment in humans is not established. Like most peptides, Fragment 176-191 is subject to gastrointestinal proteolysis that reduces oral bioavailability, which explains why subcutaneous delivery dominates research protocols [4].

Research dosing ranges in preclinical protocols typically span 25 to 1,000 mcg subcutaneously, with most fat metabolism studies using 250 to 500 mcg administered once or twice daily. These are experimental parameters from animal and laboratory research and cannot be extrapolated to human dosing due to significant differences in peptide metabolism, receptor density, and physiological responses across species.

Distribution and Metabolism

As a relatively small 16-amino acid peptide, Fragment 176-191 undergoes standard peptide degradation through circulating peptidases and tissue proteases. The disulfide bond between the two cysteine residues confers some resistance to degradation compared to linear peptides of similar size, but precise half-life data for the unmodified fragment in vivo is not well characterized in the published literature.

Adipose tissue represents the primary target compartment based on the peptide’s mechanism of action involving HSL activation and beta-3 adrenergic receptor interactions in fat cells. Distribution to muscle tissue is suggested by the thermogenic effects observed in murine models, where both adipose and muscle tissue showed beta-3 adrenergic receptor engagement [2].

Delivery Methods Under Investigation

• Subcutaneous injection: The standard delivery method across most preclinical studies; provides reliable systemic distribution and is used across the dose ranges investigated in fat metabolism research
• Intraperitoneal injection: Used in rodent research models for rapid systemic delivery; common in pharmacokinetic and mechanistic studies
• Oral administration: Tested for AOD9604 in obese rodent models with demonstrated bioactivity; the modified form’s additional stability likely contributes to oral efficacy that may not translate to the unmodified fragment
• Nanoparticle delivery: Explored in the 2022 cancer research using chitosan nanoparticles; represents an emerging delivery approach for targeted tissue delivery rather than systemic metabolic research applications [7]

Excretion and Clearance

Fragment 176-191 undergoes clearance through standard peptide degradation pathways, with metabolic fragments excreted via renal and hepatic routes. Specific clearance kinetics in humans are not published for the unmodified fragment. The absence of pharmacokinetic data from dedicated human studies is itself a significant research gap, as optimal dosing intervals and tissue exposure durations cannot be determined without this information.

Research Limitations and Evidence Gaps

Current Research Gaps

Human Clinical Data The most significant limitation of HGH Fragment 176-191 research is the near-complete absence of human clinical data for the unmodified compound. One source indicates human trials have been conducted, but comprehensive published data is not available. The GRAS expert panel finding of safety under conditions of intended use in foods represents a qualified assessment rather than the outcome of a full FDA review process. Available human analogue data from AOD9604 trials cannot be directly applied to Fragment 176-191 due to structural differences between the two compounds.

Efficacy Translation Even for AOD9604, where human trial data exists across approximately 900 subjects, efficacy outcomes were described as modest and inconsistent. Fat loss effects in humans did not meet thresholds for drug approval, despite promising preclinical data. This gap between animal model results and human outcomes is a recurring challenge in peptide research and applies directly to Fragment 176-191.

Mechanistic Understanding The cAMP/PKA pathway involvement is proposed based on extrapolation from adrenergic signaling research rather than direct mechanistic studies in Fragment 176-191 models [11]. The specific receptor responsible for the fragment’s metabolic effects has not been conclusively identified, given its low affinity for the canonical growth hormone receptor. This mechanistic gap limits the ability to predict effects, optimize research protocols, or identify potential off-target interactions.

Research Recency Primary literature specifically on Fragment 176-191 from 2020 through 2024 is sparse. The most recent identified preclinical work dates to 2022 (the cancer biology studies), and no new fat metabolism studies from this period were identified. The absence of recent dedicated research limits current understanding of the compound’s behavior in contemporary experimental models.

Methodological Considerations

• Most fat metabolism data comes from obese rodent models with genetic obesity (ob/ob mice), which may not reflect human metabolic physiology
• Study protocols vary significantly in dose, frequency, and administration route, limiting direct comparison across studies
• Long-term effects beyond typical study durations of 30 days or less are entirely uninvestigated
• Drug interaction profiles and potential effects of concurrent medications or compounds have not been systematically studied

Areas Needing Further Investigation

• Dedicated human pharmacokinetic studies for the unmodified fragment are the most critical missing data type
• Long-term safety beyond short trial durations, including potential endocrine effects, remains completely uncharacterized
• The specific receptor mediating Fragment 176-191’s metabolic effects requires identification through targeted receptor binding studies
• Cancer biology findings from 2022 computational and cell culture studies require validation in animal models before any further translational interpretation
• Cartilage and bone repair applications remain at early preclinical stage and need mechanistic characterization before meaningful translation can be assessed

Regulatory and Research Status

Current Classification

FDA Status HGH Fragment 176-191 has no FDA approval for any therapeutic indication. The compound is classified as a research chemical and cannot be legally compounded by compounding pharmacies in the United States. It does not appear on the FDA Category 1 list that permits compounding under prescription, and regulatory documents describe it as prohibited for compounding or as a substance with safety concerns in the compounding context. In February 2026, approximately 14 peptides were reclassified from FDA Category 2 to Category 1, allowing their compounding for prescription use. Fragment 176-191 was not among those reclassified, maintaining its non-approved status. The compound can only be purchased and used for legitimate laboratory research purposes, and vendors must include research-use-only labeling [10].

WADA Status The World Anti-Doping Agency prohibits HGH Fragment 176-191 in competitive athletics under the category of peptide hormones, growth factors, related substances, and mimetics. Athletes subject to anti-doping testing are prohibited from using the compound regardless of administration method. The prohibition reflects WADA’s broad approach to growth hormone-derived compounds and their potential performance implications in competitive sports.

GRAS Finding A qualified GRAS expert panel determined the peptide to be safe under conditions of intended use in foods. This is not equivalent to full FDA GRAS designation, which requires a formal FDA review process. The panel finding has limited practical regulatory significance for research use classification.

International Perspective Most major jurisdictions maintain similar research-only classifications for Fragment 176-191. The European Medicines Agency has not approved the compound for human use. No major regulatory body has granted therapeutic approval. Regulatory status for veterinary applications varies by jurisdiction but does not affect the general research-chemical classification that governs most scientific use.

Research Community Approach

Active preclinical research on Fragment 176-191 and related compounds continues primarily through academic institutions. The compound’s research-chemical status requires investigators to work within institutional biosafety and ethics frameworks applicable to experimental compounds. Compounding restrictions in the United States mean that even research-adjacent clinical investigation faces significant regulatory barriers. Institutional review board oversight applies to any human research applications.

Future Research Directions

The path toward any potential therapeutic application would require dedicated Phase I safety and pharmacokinetic studies in humans for the unmodified fragment, followed by adequately powered efficacy trials. The AOD9604 experience, where six trials and 900 subjects produced modest and inconsistent weight loss outcomes, suggests that the therapeutic bar for regulatory approval is high. The 2022 cancer biology findings represent an unexpected new direction that would require extensive validation before clinical relevance could be assessed. Regulatory clarity on the compounding pathway would be a prerequisite for any clinical investigation in the United States.

Key Research Findings

Foundational Metabolic Activity in Rat Models (1978)

Research Focus: Establishing basic metabolic activity of the 176-191 fragment versus shorter variants Key Results: Fragment 176-191 produced transient hyperglycemia and sustained plasma insulin increases in rats at 5 nmol/kg. The shorter 179-191 fragment did not produce these effects, establishing that the 176-179 segment is functionally critical for glucose and insulin modulation. Glycogenolysis was confirmed as an active metabolic pathway [1]. Significance: Foundational characterization that established the fragment’s basic metabolic activity and identified the critical functional segment Limitations: Rat data from nearly five decades ago; does not reflect current pharmacological research standards; direct human relevance unestablished

Beta-3 Adrenergic Receptor Knockout Study

Research Focus: Identifying the receptor pathway responsible for AOD9604’s fat metabolism effects using knockout mouse models Key Results: Metabolic effects of AOD9604 were significantly diminished in beta-3 adrenergic receptor knockout mice compared to wild-type controls, directly implicating this receptor in the fragment’s lipolytic and thermogenic activity [2]. Significance: Provides direct mechanistic evidence for beta-3 adrenergic receptor involvement rather than relying on pharmacological inference alone Limitations: Knockout mouse model; AOD9604 is a modified compound; findings require confirmation for unmodified Fragment 176-191

Obesity and Fat Oxidation in Murine Models

Research Focus: Weight effects and fat oxidation in genetically obese ob/ob mice using AOD9604 Key Results: Oral AOD9604 administration reduced weight gain, boosted fat oxidation, and altered adipose tissue metabolism without affecting food intake. Effects occurred without insulin resistance or glucose intolerance [4]. Significance: Demonstrated selective fat-metabolizing activity with a favorable metabolic safety profile compared to full hGH; established the ob/ob mouse model as the primary preclinical platform Limitations: Genetically obese rodent model; AOD9604 is a modified compound; oral bioavailability findings may not translate to Fragment 176-191

Ex Vivo Human Adipose Tissue Findings

Research Focus: Testing antilipogenic and lipolytic activity in human fat tissue samples from obese donors Key Results: AOD9604 enhanced lipolysis, promoted fat oxidation, and reduced lipogenesis in obese human adipose tissue ex vivo. Effects matched or exceeded those observed in rodent models for some endpoints [4]. Significance: The only data point suggesting partial translatability to human adipose biology; strengthens preclinical rationale for human investigation Limitations: Ex vivo methodology cannot replicate in vivo systemic environment; derived from AOD9604, not unmodified Fragment 176-191; does not constitute clinical evidence

AOD9604 Human Clinical Safety Profile

Research Focus: Safety and tolerability of the modified fragment analogue across six clinical trials in approximately 900 subjects Key Results: No significant changes in vital signs, laboratory parameters, ECG readings, blood glucose, or IGF-1 levels across five of six trials. No insulin resistance. Adverse events comparable to placebo. No serious adverse events reported [6]. Significance: Provides the strongest available safety signal for this class of compounds in humans; favorable profile supports further research investment Limitations: AOD9604 findings cannot be directly applied to the unmodified fragment; trials were short-term; efficacy outcomes were inconsistent

Breast Cancer Cell Enhancement Research (2022)

Research Focus: Computational docking studies and MCF-7 cell viability testing of Fragment 176-191 combined with doxorubicin in chitosan nanoparticles Key Results: High-affinity computational binding to Ki-67, MiB, and estrogen receptor. Doxorubicin inhibition constant for progesterone receptor improved approximately tenfold (139.01 nM to 14.41 nM). Enhanced MCF-7 cytotoxicity in nanoparticle delivery compared to doxorubicin alone [7]. Significance: Identified an entirely unexpected potential application area; suggests the peptide may have roles beyond fat metabolism Limitations: Computational and cell culture data only; no animal model validation; clinical relevance entirely unknown; represents the most preliminary type of evidence

Cartilage Growth in Rabbit Models

Research Focus: Cartilage repair potential using Fragment 176-191 combined with hyaluronic acid injections in rabbits Key Results: Greater cartilage growth observed with the combination versus hyaluronic acid alone [8]. Significance: Establishes cartilage repair as a legitimate preclinical research direction beyond fat metabolism Limitations: Single animal model study; mechanistic basis not characterized; requires replication in multiple models before conclusions can be drawn

Frequently Asked Questions

What is HGH Fragment 176-191?

HGH Fragment 176-191 is a synthetic research peptide derived from amino acids 176 through 191 at the C-terminal end of full human growth hormone. Scientists study it because this specific region of the growth hormone sequence appears to contain the fat-metabolism activity of the larger protein, without the growth-promoting effects of the full hormone.

How does HGH Fragment 176-191 differ from full human growth hormone?

Unlike full human growth hormone, Fragment 176-191 does not significantly stimulate IGF-1 production and shows low affinity for the canonical growth hormone receptor. This means it lacks the growth-promoting, tissue-building, and insulin resistance-generating effects associated with full hGH. Research focuses specifically on its selective fat metabolism properties as a result of these differences.

What does research show about HGH Fragment 176-191 and fat metabolism?

Preclinical studies in obese rodent models show that AOD9604, a modified form of Fragment 176-191, reduces weight gain and increases fat oxidation without affecting food intake or causing insulin resistance. Ex vivo studies using human adipose tissue samples confirmed antilipogenic and lipolytic effects in human fat cells, though in vivo human data for the unmodified fragment is extremely limited.

Is HGH Fragment 176-191 approved for human use?

No. HGH Fragment 176-191 has no FDA approval for any therapeutic indication and is classified as a research chemical restricted to laboratory use. It cannot be legally compounded in the United States and is not approved by any major regulatory body for human therapeutic applications. It is also prohibited by WADA in competitive athletics.

How long has HGH Fragment 176-191 been studied?

Research on this peptide dates to 1978, when foundational rat studies established its basic metabolic properties. Research on the closely related modified form AOD9604 extended into human trials covering approximately 900 subjects across six studies. The most recent primary research on Fragment 176-191 itself was published in 2022, focusing on breast cancer biology applications. Despite nearly five decades of intermittent research, comprehensive human clinical data for the unmodified compound remains absent.

References

1. Ng, F.M., & Bornstein, J. (1978). Hyperglycemic and insulinotropic activities of a C-terminal fragment of human growth hormone. Biochemical and Biophysical Research Communications, 85(1), 230-237. PubMed

2. Heffernan, M., Summers, R.J., Thorburn, A., Ogru, E., Gianello, R., Jiang, W.J., & Ng, F.M. (2001). The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knockout mice. Endocrinology, 142(12), 5182-5189. PubMed

3. Kanaley, J.A., Weatherup-Dentes, M.M., Jaynes, E.B., & Hartman, M.L. (1999). Obesity attenuates the growth hormone response to exercise. Journal of Clinical Endocrinology and Metabolism, 84(9), 3156-3161. PubMed

4. Ng, F.M., Sun, J., Sharma, L., Libinaka, R., Jiang, W.J., & Gianello, R. (2000). Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Hormone Research, 53(6), 274-278. PubMed

5. Lafontan, M., & Berlan, M. (1993). Fat cell adrenergic receptors and the control of white and brown fat cell function. Journal of Lipid Research, 34(7), 1057-1091. PubMed

6. Stier, H., Fahey, M., & Rice, M.A. (2013). AOD9604: A review of its safety and tolerability profile in clinical studies. Clinical Obesity, 3(6), 167-175. PubMed

7. Hamad, A.A., & Al-Salihi, A.R. (2022). HGH fragment 176-191 peptide enhances the cytotoxic effects of doxorubicin-loaded chitosan nanoparticles against MCF-7 breast cancer cells. Journal of Pharmaceutical Sciences, 111(8), 2352-2360. PubMed

8. Kim, S.H., Kim, S., & Fernandes, J.A. (2015). Effect of HGH fragment 176-191 with hyaluronic acid on cartilage growth in a rabbit model. Journal of Orthopaedic Research, 33(6), 867-875. PubMed

9. Jiang, W.J., Gianello, R., & Ng, F.M. (1998). Structure-activity relationships of lipolytic fragments of human growth hormone. Journal of Molecular Endocrinology, 21(2), 147-155. PubMed

10. U.S. Food and Drug Administration. (2024). Bulk drug substances nominated for use in compounding under section 503A of the Federal Food, Drug, and Cosmetic Act. FDA Docket. FDA

11. Litosch, I., & Fain, J.N. (1986). Regulation of phosphoinositide breakdown by guanine nucleotides. Life Sciences, 39(3), 187-194. PubMed

12. Carey, A.L., Steinberg, G.R., Macaulay, S.L., Thomas, W.G., Holmes, A.G., Ramm, G., Prelovsek, O., Hohnen-Behrens, C., Watt, M.J., James, D.E., Kemp, B.E., Pedersen, B.K., & Febbraio, M.A. (2006). Interleukin-6 increases insulin-stimulated glucose disposal in humans and glucose uptake and fatty acid oxidation in vitro via AMP-activated protein kinase. Diabetes, 55(10), 2688-2697. PubMed

13. Fruhbeck, G., Gomez-Ambrosi, J., Muruzabal, F.J., & Burrell, M.A. (2001). The adipocyte: a model for integration of endocrine and metabolic signaling in energy metabolism regulation. American Journal of Physiology – Endocrinology and Metabolism, 280(6), E827-E847. PubMed

14. Moller, N., & Jorgensen, J.O. (2009). Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects. Endocrine Reviews, 30(2), 152-177. PubMed

15. Carmignac, D.F., Gabrielsson, B.G., & Robinson, I.C. (1993). Growth hormone-binding protein in the rat: effects of altered growth hormone status. Endocrinology, 133(6), 2445-2452. PubMed

16. Gkantzou, E., & Chatzidaki, M.D. (2023). Peptides as emerging tools for obesity management: mechanisms and research perspectives. Molecules, 28(4), 1845. PubMed